SELLAS Life Sciences Strengthens Cash Reserves and Expands Clinical Pipeline Amid Pivotal 2026 Milestones

Financial Position at All-Time Highs with Over $114 Million in Cash

SELLAS Life Sciences (NASDAQ: SLS) reported financial results for 2025, revealing a transformed balance sheet and robust cash reserves headed into 2026. As of December 31, 2025, cash and cash equivalents stood at $71.79 million, further fortified by an additional $42.6 million raised via warrant exercises in Q1 2026. This places SELLAS in its strongest financial position to date, primed to fund intensive clinical activity and new studies.

GPS and SLS009 Clinical Advances Signal Major 2026 Data Catalysts

The company’s lead program—Galinpepimut-S (GPS)—remains on track with a pivotal Phase 3 REGAL trial in acute myeloid leukemia (AML). As of December 2025, 72 of the 80 necessary events had been recorded; the final analysis is slotted for announcement upon reaching the 80th event, triggering unblinding and topline data disclosure. If successful, GPS could become the first and best-in-class immunotherapeutic in this difficult-to-treat AML population.

Meanwhile, SLS009 (tambiciclib), Sellas’ CDK9 inhibitor, is making waves across both relapsed/refractory and newly diagnosed AML settings. Positive Phase 2 data presented at ASH 2025 showed response rates of 46% overall and as high as 57% in patients with tough-to-treat genetic mutations (ASXL1, TP53). The median overall survival in certain subgroups exceeded 8.9 months—much higher than the 2.6-month expectation for this patient set. Importantly, no dose-limiting toxicities or treatment-related deaths were observed. Following encouraging results, SLS009 trials have expanded into earlier lines of AML therapy in both the US and, via a strategic partnership with IMPACT-AML, across Europe.

Preclinical Results Build Confidence in Pipeline Breadth

The company also showcased promising preclinical data for SLS009 at AACR 2026 and ESMO 2025. Laboratory studies revealed SLS009 accelerates apoptosis in AML cell lines harboring high-risk mutations and confers survival benefits in T-cell prolymphocytic leukemia (T-PLL) xenograft models, especially when combined with venetoclax. These findings both validate the CKD9 inhibition strategy and open doors for broader hematologic applications.

Cost Controls and Warrant Exercises Enhance Shareholder Buffer

Cost discipline was reflected in the annual numbers, with R&D expenses decreasing to $16.02 million in 2025—down from $19.10 million the year prior—mainly driven by clinical trial completion. General and administrative costs were virtually flat year over year. The surge in cash and equity capital, driven by $67.2 million in gross warrant proceeds during 2025 and another $42.6 million in the first quarter of 2026, underscores management’s ability to build a significant runway for execution.

Key Numbers at a Glance

Outlook: Major Data Milestones Could Drive Next Value-Inflection

With more than $114 million on hand—and clinical and preclinical data fueling optimism—SELLAS is positioned for a milestone-rich 2026. The imminent Phase 3 REGAL trial results represent a possible turning point for both the company and GPS. Should efficacy and safety signals hold up, GPS and SLS009 have the potential to change the treatment paradigm in AML and related hematologic cancers.

Investors and the wider oncology community will be watching closely, as SELLAS seeks to translate promising trial momentum and a fortified financial base into real-world results over the coming months.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI